| |
| |
|
| Insider
Information: |
Fickenscher James E |
| Relationship: |
|
| City: |
Norristown |
| State: |
PA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
391,266 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$2,187,177 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
391,266 |
|
|
| Total
Value |
$2,187,177 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
3
|
|
Stock
price went up :
|
1
|
1
|
| Stock
price went down : |
0
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
1.0
|
1.0
|
| Percentage
Gain/Loss : |
 64.3%
|
40.4%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Antares Pharma Inc |
ATRS |
Senior Vice President ... |
2016-06-02 |
391,266 |
2014-12-11 |
0 |
Premium* |
|
|
Zynerba Pharmaceuticals, Inc. |
ZYNE |
|
2023-10-10 |
0 |
2016-12-06 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
22 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ZYNE |
Zynerba Pharmaceuticals, ... |
Chief Financial Officer |
• • – |
2023-10-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(548,087) |
0 |
0 |
- |
|
| ZYNE |
Zynerba Pharmaceuticals, ... |
Chief Financial Officer |
• • – |
2023-10-10 |
4 |
A |
$0.00 |
$0 |
D/D |
170,000 |
425,000 |
0 |
- |
|
| ZYNE |
Zynerba Pharmaceuticals, ... |
Chief Financial Officer |
• – – |
2023-09-13 |
4 |
S |
$1.33 |
$11,929 |
D/D |
(8,998) |
378,087 |
0 |
% |
|
| ZYNE |
Zynerba Pharmaceuticals, ... |
Chief Financial Officer |
• – – |
2023-09-12 |
4 |
A |
$0.00 |
$0 |
D/D |
31,200 |
387,085 |
0 |
- |
|
| ZYNE |
Zynerba Pharmaceuticals, ... |
Chief Financial Officer |
• – – |
2023-02-08 |
4 |
D |
$0.60 |
$3,903 |
D/D |
(6,544) |
355,885 |
0 |
- |
|
| ZYNE |
Zynerba Pharmaceuticals, ... |
Chief Financial Officer |
• – – |
2023-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
22,547 |
362,429 |
0 |
- |
|
| ZYNE |
Zynerba Pharmaceuticals, ... |
Chief Financial Officer |
• – – |
2023-02-01 |
4 |
D |
$0.60 |
$3,528 |
D/D |
(5,927) |
339,882 |
0 |
- |
|
| ZYNE |
Zynerba Pharmaceuticals, ... |
Chief Financial Officer |
• – – |
2023-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
21,073 |
345,809 |
0 |
- |
|
| ZYNE |
Zynerba Pharmaceuticals, ... |
Chief Financial Officer |
• – – |
2023-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
170,000 |
324,736 |
0 |
- |
|
| ZYNE |
Zynerba Pharmaceuticals, ... |
Chief Financial Officer |
• – – |
2023-01-23 |
4 |
S |
$0.60 |
$10,622 |
D/D |
(17,769) |
154,736 |
0 |
% |
|
| ZYNE |
Zynerba Pharmaceuticals, ... |
Chief Financial Officer |
• – – |
2022-07-19 |
4 |
S |
$1.10 |
$6,614 |
D/D |
(6,013) |
172,505 |
0 |
% |
|
| ZYNE |
Zynerba Pharmaceuticals, ... |
Chief Financial Officer |
• – – |
2022-07-18 |
4 |
A |
$0.00 |
$0 |
D/D |
20,800 |
178,518 |
0 |
- |
|
| ZYNE |
Zynerba Pharmaceuticals, ... |
Chief Financial Officer |
• – – |
2022-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
85,000 |
157,718 |
0 |
- |
|
| ZYNE |
Zynerba Pharmaceuticals, ... |
Chief Financial Officer |
• – – |
2021-01-21 |
4 |
A |
$0.00 |
$0 |
D/D |
52,000 |
72,718 |
0 |
- |
|
| ZYNE |
Zynerba Pharmaceuticals, ... |
Chief Financial Officer |
• – – |
2018-08-06 |
4 |
B |
$5.97 |
$50,842 |
D/D |
8,518 |
20,718 |
2.74 |
- |
|
| ZYNE |
Zynerba Pharmaceuticals, ... |
Chief Financial Officer |
• – – |
2017-05-12 |
4 |
B |
$19.82 |
$103,064 |
D/D |
5,200 |
12,200 |
2.74 |
- |
|
| ZYNE |
Zynerba Pharmaceuticals, ... |
Chief Financial Officer |
• – – |
2016-12-07 |
4 |
B |
$14.03 |
$56,120 |
D/D |
4,000 |
7,000 |
2.74 |
- |
|
| ZYNE |
Zynerba Pharmaceuticals, ... |
Chief Financial Officer |
• – – |
2016-12-06 |
4 |
B |
$14.15 |
$42,450 |
D/D |
3,000 |
3,000 |
2.74 |
- |
|
| ATRS |
Antares Pharma Inc |
Senior Vice President & CFO |
• – – |
2016-06-02 |
4 |
A |
$1.12 |
$135,576 |
D/D |
121,050 |
391,266 |
0 |
- |
|
| ATRS |
Antares Pharma Inc |
Senior Vice President & CFO |
• – – |
2016-03-18 |
4 |
B |
$0.72 |
$97,200 |
D/D |
135,000 |
270,216 |
2.74 |
- |
|
| ATRS |
Antares Pharma Inc |
Senior Vice President & CFO |
• – – |
2015-05-28 |
4 |
A |
$0.00 |
$0 |
D/D |
95,216 |
135,216 |
0 |
- |
|
| ATRS |
Antares Pharma Inc |
Senior Vice President & CFO |
• – – |
2014-12-11 |
4 |
B |
$2.50 |
$99,800 |
D/D |
40,000 |
40,000 |
2.74 |
- |
|
22 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
